Encompass Health Corporation $EHC Shares Sold by Kennedy Capital Management LLC

Kennedy Capital Management LLC trimmed its holdings in shares of Encompass Health Corporation (NYSE:EHC) by 13.4% in the 4th quarter, HoldingsChannel.com reports. The fund owned 61,063 shares of the company’s stock after selling 9,474 shares during the quarter. Kennedy Capital Management LLC’s holdings in Encompass Health were worth $6,481,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds have also bought and sold shares of EHC. WPG Advisers LLC lifted its stake in Encompass Health by 73.3% during the 4th quarter. WPG Advisers LLC now owns 324 shares of the company’s stock valued at $34,000 after acquiring an additional 137 shares during the period. Flagship Harbor Advisors LLC acquired a new position in Encompass Health during the fourth quarter valued at $37,000. Assetmark Inc. lifted its position in Encompass Health by 88.1% during the third quarter. Assetmark Inc. now owns 299 shares of the company’s stock valued at $38,000 after purchasing an additional 140 shares during the period. Caitong International Asset Management Co. Ltd lifted its position in Encompass Health by 36,200.0% during the third quarter. Caitong International Asset Management Co. Ltd now owns 363 shares of the company’s stock valued at $46,000 after purchasing an additional 362 shares during the period. Finally, Covestor Ltd lifted its position in Encompass Health by 24.4% during the fourth quarter. Covestor Ltd now owns 540 shares of the company’s stock valued at $57,000 after purchasing an additional 106 shares during the period. 97.25% of the stock is currently owned by institutional investors and hedge funds.

Encompass Health Stock Performance

EHC opened at $99.13 on Tuesday. The company has a debt-to-equity ratio of 0.76, a current ratio of 1.17 and a quick ratio of 1.17. The firm has a fifty day moving average price of $104.35 and a 200 day moving average price of $104.47. Encompass Health Corporation has a 1 year low of $92.77 and a 1 year high of $127.99. The stock has a market cap of $9.83 billion, a P/E ratio of 16.55, a P/E/G ratio of 2.21 and a beta of 0.72.

Encompass Health (NYSE:EHC) last posted its earnings results on Thursday, April 30th. The company reported $1.60 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.51 by $0.09. Encompass Health had a net margin of 10.04% and a return on equity of 18.28%. The firm had revenue of $1.59 billion during the quarter, compared to analysts’ expectations of $1.57 billion. During the same period in the previous year, the business posted $1.37 EPS. The business’s revenue was up 9.0% compared to the same quarter last year. Encompass Health has set its FY 2026 guidance at 5.890-6.110 EPS. Equities research analysts anticipate that Encompass Health Corporation will post 5.97 earnings per share for the current year.

Encompass Health Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Wednesday, July 15th. Investors of record on Wednesday, July 1st will be paid a $0.19 dividend. This represents a $0.76 annualized dividend and a dividend yield of 0.8%. The ex-dividend date is Wednesday, July 1st. Encompass Health’s payout ratio is currently 12.69%.

Wall Street Analyst Weigh In

EHC has been the subject of a number of research reports. Weiss Ratings restated a “buy (b-)” rating on shares of Encompass Health in a research report on Monday, June 8th. Leerink Partners set a $152.00 target price on shares of Encompass Health in a research report on Friday, May 22nd. TD Cowen initiated coverage on shares of Encompass Health in a research report on Thursday, May 28th. They set a “buy” rating and a $125.00 target price for the company. Wall Street Zen upgraded shares of Encompass Health from a “hold” rating to a “buy” rating in a research report on Saturday, May 2nd. Finally, Barclays decreased their target price on shares of Encompass Health from $153.00 to $140.00 and set an “overweight” rating for the company in a research note on Tuesday, May 5th. One research analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating and one has assigned a Hold rating to the stock. According to MarketBeat, Encompass Health presently has a consensus rating of “Buy” and a consensus price target of $143.86.

Insiders Place Their Bets

In other Encompass Health news, EVP Patrick William Tuer sold 682 shares of the company’s stock in a transaction on Monday, May 11th. The shares were sold at an average price of $104.56, for a total transaction of $71,309.92. Following the completion of the transaction, the executive vice president directly owned 24,755 shares in the company, valued at approximately $2,588,382.80. This represents a 2.68% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Corporate insiders own 1.80% of the company’s stock.

Encompass Health Company Profile

Encompass Health Corporation is a leading provider of post‐acute healthcare services in the United States, operating a comprehensive network of inpatient rehabilitation hospitals and home health and hospice agencies. Its inpatient rehabilitation hospitals offer intensive therapy programs for patients recovering from conditions such as stroke, brain injury, spinal cord injury, cardiac and pulmonary disorders, and orthopedic procedures. Through its home health segment, Encompass Health delivers skilled nursing, physical therapy, occupational therapy and speech therapy to patients in the comfort of their homes, while its hospice services provide end‐of‐life care focused on symptom management and emotional support for patients and families.

Founded in 1984 as HealthSouth Corporation and rebranded as Encompass Health in 2018, the company has grown organically and through acquisitions to serve patients across more than 30 states.